27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The FDA has slapped a partial clinical hold on the early-stage program for one of Kura Oncology Inc’s (NASDAQ:KURA) cancer drugs following a patient’s death in a clinical trial.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Kura reported that the Phase 1b study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probe the death.
- Patients already on the drug can continue taking it.
- According to Kura, the death was “potentially associated with differentiation syndrome, a known adverse event related to differentiating agents in the treatment of AML.”
- Until the partial clinical hold is resolved, Kura is suspending guidance on completing enrollment in the KOMET-001 Phase 1b study and determining the recommended Phase 2 dose of KO-539.
- Earlier, the Company expected to complete enrollment in Q1 of 2022.
- The oral drug is designed to block the interaction of two proteins - menin and KMT2A/MLL.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: KURA shares fell 16.9% at $13.81 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.